Enteca 0.5 mg (Tablet)
Unit Price: ৳ 48.00 (1 x 10: ৳ 480.00)
Strip Price: ৳ 480.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Entecavir |
| Company | Renata limited |
Indications
- Treatment of chronic hepatitis B virus infection in adults
- Treatment of chronic hepatitis B virus infection in pediatric patients 2 years of age and older
- Active viral replication
- Persistent elevation in serum aminotransferases (ALT or AST)
- Histologically active disease
Pharmacology
- Competes with natural substrate deoxyguanosine triphosphate
- Inhibits all three activities of the HBV polymerase
- Base priming
- Reverse transcription of the negative strand from the pregenomic messenger RNA
- Synthesis of the positive strand of HBV DNA
- Incorporated into the DNA upon activation by kinases
Dosage & Administration
- Recommended dose for nucleoside-treatment-naive adults and adolescents 16 years of age: 0.5 mg once daily
- Recommended dose for Lamivudine-refractory patients or those with known resistance mutations: 1 mg once daily
- Recommended dose for patients with decompensated liver disease (adults): 1 mg once daily
- Administered on an empty stomach
- Missed Dose: Do not take a double dose
Interaction
- No significant drug interactions with Lamivudine or Adefovir dipivoxil
- Effects of co-administration with other drugs eliminated through renal or known to affect renal function have not been evaluated
Contraindications
- Hypersensitivity to Entecavir or any component of the product
Side Effects
- Headache
- Fatigue
- Dizziness
- Nausea
Pregnancy & Lactation
- No data on the effect of Entecavir on transmission of HBV from mother to infant
- Precautions should be taken
- Not known whether it is excreted in human milk
- Mothers should be instructed not to breastfeed if taking Entecavir
Precautions & Warnings
- Lactic acidosis reported with the use of nucleoside analogues alone or in combination with antiretrovirals
- Exacerbations of hepatitis after discontinuation of treatment reported
- Safety and effectiveness not established in pediatric patients below the age of 2 years
- Care should be taken in dose selection for geriatric patients
- Dose adjustment in renal impairment recommended
Use in Special Populations
- Safety and effectiveness not established in pediatric patients below the age of 2 years
- Clinical studies did not include sufficient numbers of subjects aged 65 years and over
- Dose adjustment recommended for patients with impaired renal function
Overdose Effects
- No reported experience of Entecavir overdosage in patients
- Healthy subjects who received high doses had no unexpected adverse events
- Patients must be monitored for evidence of toxicity if overdosage occurs
Therapeutic Class
- Hepatic viral infections (Hepatitis B)
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from light
- Keep out of the reach of children